BioLine RxBLRX +1.73%23 PB Ratio is 0.81 as of Jun. 26, 2026, which is 16% below its 10-year median of 0.96. GuruFocus rates BLRX with a GF Score™ of 23/100. The stock has 5 warning signs investors should review. Among 1,232 Biotechnology companies, BioLine Rx ranks better than 87.74% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), BioLine Rx's share price is $3.12. BioLine Rx's Book Value per Share for the quarter that ended in Mar. 2026 was $3.83. Hence, BioLine Rx's PB Ratio of today is 0.81.
The historical rank and industry rank for BioLine Rx's PB Ratio or its related term are showing as below:
BLRX'
s PB Ratio Range Over the Past 10 Years
Min: 0.59 Med: 0.96 Max: 10.56
Current: 0.76
During the past 13 years, BioLine Rx's highest PB Ratio was 10.56. The lowest was 0.59. And the median was 0.96.
BLRX's PB Ratio is ranked better than 87.74% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs BLRX: 0.76
During the past 12 months, BioLine Rx's average Book Value Per Share Growth Rate was -32.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -49.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -42.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -40.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BioLine Rx was 8.10% per year. The lowest was -52.60% per year. And the median was -33.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BioLine Rx PB Ratio Related Terms
BioLine Rx PB Ratio Historical Data
* Premium members only.
The historical data trend for BioLine Rx's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioLine Rx's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLine Rx PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLine Rx's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioLine Rx's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
BioLine Rx's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioLine Rx (BLRX) has a PB Ratio of 0.81 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioLine Rx and its competitors. This is 16% below median its historical median of 0.96. Over the past decade, BioLine Rx's PB Ratio has ranged from 0.59 to 10.56. According to the industry distribution chart, BioLine Rx ranks #151 out of 1232 companies in the Biotechnology industry, placing it in the top 12.3%.
Is BioLine Rx's PB Ratio too high?
BioLine Rx's current PB Ratio of 0.81 is 16% below median its 10-year median of 0.96. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 10.56. The Biotechnology industry median PB Ratio is 2.80. BioLine Rx's value of 0.81 is 71.1% below this industry median. Based on the distribution chart, BioLine Rx ranks #151 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioLine Rx has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLine Rx ranks #151 out of 1232 companies for PB Ratio. This places BioLine Rx in the top 12% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. BioLine Rx's value of 0.81 is 71.1% below this benchmark. Historically, BioLine Rx's own PB Ratio has ranged from 0.59 to 10.56 over the past decade. While the company's 10-year median is 0.96 vs. the industry median of 2.80, BioLine Rx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLine Rx's current PB Ratio of 0.81 is 71.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioLine Rx and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLine Rx's current PB Ratio is 0.81, which is 16% below median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (BLRX) has a current PB Ratio of 0.81. The current PB Ratio is 0.81, which is 16% below median its 10-year median of 0.96 and 71.1% below the Biotechnology industry median of 2.80. BioLine Rx's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioLine Rx (BLRX), the current PB Ratio is 0.81 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
23GF Score
Get the complete analysis for BLRX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLRX has been successfully added to your 
